Detalhe da pesquisa
1.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
2.
Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Leuk Lymphoma
; 65(2): 235-241, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38264906
3.
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
Leuk Lymphoma
; 63(12): 2889-2896, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35972020
4.
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
J Clin Oncol
; 39(20): 2257-2265, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909449